Division of Genetic Epidemiology, Central Institute of Mental Health, Mannheim, Germany.
Schizophr Res. 2010 May;118(1-3):98-105. doi: 10.1016/j.schres.2009.12.025. Epub 2010 Jan 18.
Dysbindin (DTNBP1) is a widely studied candidate gene for schizophrenia (SCZ); however, inconsistent results across studies triggered skepticism towards the validity of the findings. In this HapMap-based study, we reappraised the association between Dysbindin and SCZ in a large sample of German ethnicity.
Six hundred thirty-four cases with DSM-IV SCZ, 776 controls, and 180 parent-offspring trios were genotyped for 38 Dysbindin SNPs. We also studied two phenotypically-defined subsamples: 147 patients with a positive family history of SCZ (FH-SCZ+) and SCZ patients characterized for cognitive performance with Trail-Making Tests A and B (TMT-A: n=219; TMT-B: n=247). Given previous evidence of gene-gene interactions in SCZ involving the COMT gene, we also assessed epistatic interactions between Dysbindin markers and 14 SNPs in COMT.
No association was detected between Dysbindin markers and SCZ, or in the FH-SCZ+ subgroup. Only one marker (rs1047631, previously reported to be part of a risk haplotype), showed a nominally significant association with performance on TMT-A and TMT-B; these findings did not remain significant after correction for multiple comparisons. Similarly, no pair-wise epistatic interactions between Dysbindin and COMT markers remained significant after correction for 504 pair-wise comparisons.
Our results, based on one of the largest samples of European Caucasians and using narrowly-defined criteria for SCZ, do not support the etiological involvement of Dysbindin markers in SCZ. Larger samples may be needed in order to unravel Dysbindin's possible role in the genetic basis of proposed intermediate phenotypes of SCZ or to detect epistatic interactions.
Dysbindin(DTNBP1)是精神分裂症(SCZ)的一个广泛研究的候选基因;然而,研究结果的不一致引发了对这些发现有效性的怀疑。在这项基于 HapMap 的研究中,我们在一个大型德国人群中重新评估了 Dysbindin 与 SCZ 之间的关联。
634 例 DSM-IV SCZ 患者、776 例对照者和 180 对父母-子女三系被 38 个 Dysbindin SNP 进行了基因分型。我们还研究了两个表型定义的亚组:147 例 SCZ 阳性家族史患者(FH-SCZ+)和 SCZ 患者的认知表现特征,包括 Trail-Making Tests A 和 B(TMT-A:n=219;TMT-B:n=247)。鉴于先前涉及 COMT 基因的 SCZ 基因-基因相互作用的证据,我们还评估了 Dysbindin 标记物与 COMT 中 14 个 SNP 之间的上位性相互作用。
没有发现 Dysbindin 标记物与 SCZ 或 FH-SCZ+亚组之间存在关联。只有一个标记物(rs1047631,先前报道为风险单倍型的一部分)与 TMT-A 和 TMT-B 的表现呈名义上显著相关;这些发现经过多次比较校正后不再显著。同样,经过 504 对比较的校正,Dysbindin 和 COMT 标记物之间没有任何一对上位性相互作用仍然显著。
我们的结果基于欧洲白种人群中最大的样本之一,并使用严格定义的 SCZ 标准,不支持 Dysbindin 标记物在 SCZ 发病机制中的作用。可能需要更大的样本才能揭示 Dysbindin 可能在 SCZ 中间表型的遗传基础中或检测上位性相互作用中的作用。